Benzinga | Jan 5, 2022 09:43AM EST

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $170

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $150 to $170.